Key Documents

View All Documentation

N-004

Naloxone solution

Name: Naloxone solution
Brand: CERILLIAN

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant^®

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):

C₁₉H₂₁NO₄

CAS Number:

465-65-6

Molecular Weight:

327.37

NACRES:

NA.24

PubChem Substance ID:

329818392

UNSPSC Code:

41116107

EC Number:

200-659-6

MDL number:

MFCD00242634

Technical Service

Need help? Our team of experienced scientists is here for you.

Let Us Assist

Properties

grade

certified reference material

Quality Level

300

form

liquid

feature

Snap-N-Spike^®/Snap-N-Shoot^®

packaging

ampule of 1 mL

manufacturer/tradename

Cerilliant^®

concentration

1.0 mg/mL in methanol

technique(s)

gas chromatography (GC): suitable, liquid chromatography (LC): suitable

application(s)

forensics and toxicology

format

single component solution

storage temp.

2-8°C

SMILES string

Oc1ccc2C[C@H]3N(CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O)CC=C

InChI

1S/C19H21NO4/c1-2-8-20-9-7-18-15-11-3-4-12(21)16(15)24-17(18)13(22)5-6-19(18,23)14(20)10-11/h2-4,14,17,21,23H,1,5-10H2/t14-,17+,18+,19-/m1/s1

InChI key

UZHSEJADLWPNLE-GRGSLBFTSA-N

Gene Information

human ... OPRD1(4985), OPRK1(4986), OPRM1(4988)

Description

General description

Naloxone is an opiate drug used to counter the effects of opioid overdose. This certified solution standard is applicable for use in LC/MS or GC/MS applications such as clinical toxicology and forensic analysis. Naloxone is sold under the trade names Narcan^®, Nalone, and Narcan^®ti.

Legal Information

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany

Narcan is a registered trademark of Endo Pharmaceuticals Inc.

Snap-N-Shoot is a registered trademark of Cerilliant Corporation

Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

Still not finding the right product?

Explore all of our products under Naloxone solution

pictograms

GHS02,GHS06,GHS08

signalword

Danger

hcodes

H225,H301 + H311 + H331,H370

pcodes

P210 - P233 - P280 - P301 + P310 - P303 + P361 + P353 - P304 + P340 + P311

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

target_organs

Eyes,Central nervous system

Storage Class

3 - Flammable liquids

wgk

WGK 2

flash_point_f

49.5 °F - closed cup

flash_point_c

9.7 °C - closed cup

Regulatory Information

危险化学品

This item has

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Articles

Benefits of Ascentis Express Phenyl-Hexyl over Biphenyl for the Separation of Pain Management Opiates

Although both biphenyl and phenyl-hexyl phases can resolve these compounds, the former exhibits excellent peak shape and substantially less silanol-derived ion exchange activity.

Suboxone misuse along the opiate maintenance treatment pathway.

R Terry Furst

Journal of addictive diseases, 32(1), 53-67 (2013-03-14)

This study explores strategies that Suboxone misusers utilize while in drug treatment. Ethnographic interviews were conducted with 14 patients who had cycled in and out of Suboxone treatment. The objective of the study is to identify strategies implemented by patients

A preliminary study comparing methadone and buprenorphine in patients with chronic pain and coexistent opioid addiction.

Anne M Neumann et al.

Journal of addictive diseases, 32(1), 68-78 (2013-03-14)

Patients with opioid addiction who receive prescription opioids for treatment of nonmalignant chronic pain present a therapeutic challenge. Fifty-four participants with chronic pain and opioid addiction were randomized to receive methadone or buprenorphine/naloxone. At the 6-month follow-up examination, 26 (48.1%)

Importance of the correct diagnosis of opioid-induced respiratory depression in adult cancer patients and titration of naloxone.

Jason Boland et al.

Clinical medicine (London, England), 13(2), 149-151 (2013-05-18)

Opioids can induce respiratory depression by invoking a centrally mediated decrease in involuntary respiratory rate, which in severe cases can cause a decrease in oxygen saturation. If respiratory depression is opioid induced, both low respiratory rate and low oxygen saturation

View All Related Papers

Global Trade Item Number

SKU	GTIN
N-004-1ML	04061834081418